Ann Lab Med 2017; 37(4): 327-330  
Comparison of Two Apheresis Systems of COBE and Optia for Autologous Peripheral Blood Stem Cell Collection
Se-Na Lee, R.N.1, Ji Yeon Sohn, M.D.1, Jung Hee Kong, R.N.1, Hyeon Seok Eom, M.D.2,4, Hyewon Lee, M.D.2, and Sun-Young Kong, M.D.1,3,4
Department of Laboratory Medicine1, Center for Diagnostic Oncology; Center for Hematologic Malignancy2; Translational Epidemiology Branch3, Hospital and Research Institute; Department of System Cancer Science4, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea
Correspondence to: Sun-Young Kong
Department of Laboratory Medicine, Center for Diagnostic Oncology, Translational Epidemiology Research Branch, Hospital and Research Institute, Department of System Cancer Science, Graduate School of Cancer Science and Policy, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea
Tel: +82-31-920-1735
Fax: +81-31-920-1268
Received: August 8, 2016; Revised: December 12, 2016; Accepted: March 16, 2017; Published online: July 1, 2017.
© The Korean Society for Laboratory Medicine. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Peripheral blood stem cell (PBSC) transplantation following myeloablative therapy is a mainstay of treatment for various types of malignancies. This study aimed to evaluate the differences between the Optia MNC and COBE Spectra MNC systems (Terumo BCT, Japan) according to apheresis procedures and the parameters of apheresis, products, and collection. The clinical data of 74 patients who underwent autologous PBSC collection from July 2012 to July 2015 were reviewed retrospectively. The patients comprised 48 (65%) men and 26 (35%) women with a median age of 56 yr (range, 23–66 yr). Of 216 procedures, 111 (51%) and 105 (49%) were processed by using COBE and Optia MNC, respectively. PBSC collection rates, throughput, numbers of stem cells retrieved, collection efficacy, and platelet loss were compared. There were no significant differences in the median CD34+ cell counts of collected products (0.61×108 vs 0.94×108), CD34 collection efficiency (43.5% vs 42.1%), and loss of platelets (40.1% vs 44.7%). The Spectra Optia MNC apheresis system was comparable to the COBE Spectra system in collecting autologous CD34+ hematopoietic stem cells and retention of platelets.
Keywords: Autologous, Collection, Efficiency, Stem cell, Apheresis

This Article



Indexed/Covered by